W. Hsu

发表

Distinguishing human peripheral blood CD16+ myeloid cells based on phenotypic characteristics

J. Hsu, Ahmed H. Mekkawy, P. Hogarth, 2019, Journal of leukocyte biology.

Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death.

G. Giaccone, B. Teicher, Justine N. McCutcheon, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan

Jih-Hsiang Lee, Yih-Leong Chang, J. Shih, 2018, Journal of Cancer.

CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential

P. Silveira, X. Ju, G. Clark, 2019, Front. Immunol..

The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.

A. Ashraf, S. Fleming, A. Schwarer, 2017, Blood advances.

Anti-Mouse CD83 Monoclonal Antibody Targeting Mature Dendritic Cells Provides Protection Against Collagen Induced Arthritis

D. Baker, F. Kupresanin, P. Silveira, 2022, Frontiers in Immunology.

Combinatorial treatment of bone marrow stem cells and stromal cell-derived factor 1 improves glycemia and insulin production in diabetic mice

M. Atkinson, M. Phillips, W. Hsu, 2011, Molecular and Cellular Endocrinology.

Chk1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in small cell lung cancer by promoting mitotic cell death

G. Giaccone, B. Teicher, B. Kallakury, 2019 .

Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells

J. Yang, A. Lin, W. Hsu, 2021, Cancers.

The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83+-Activated T Cell Population

J. Hsu, B. Fazekas de St. Groth, H. McGuire, 2016, The Journal of Immunology.

Bone Marrow Graft-Versus-Host Disease in Major Histocompatibility Complex-Matched Murine Reduced-Intensity Allogeneic Hemopoietic Cell Transplantation

L. Bendall, K. Bradstock, P. Silveira, 2017, Transplantation.

EMT is associated with, but does not drive resistance to ALK inhibitors among EML4‐ALK non‐small cell lung cancer

Yi-Song Wang, G. Giaccone, W. Hsu, 2016, Molecular Oncology.

Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.

Jih-Hsiang Lee, Yih-Leong Chang, J. Shih, 2019, European journal of cancer.

Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations

Yi-Song Wang, G. Giaccone, E. Petricoin, 2017, Scientific Reports.

Overview of current systemic management of EGFR-mutant NSCLC

Jie Yang, T. Mok, H. Loong, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Necrotizing Fasciitis Extending to the Neck After Extracorporeal Shock Wave Lithotripsy: A Case Report

Marcelo Chen, W. Hsu, Chu-Hao Weng, 2022, Iranian Journal of Radiology.

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC

Jih-Hsiang Lee, J. Shih, J. Yang, 2020, JTO clinical and research reports.

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small-Cell Lung Cancer

Jih-Hsiang Lee, J. Shih, Yeun-Chung Chang, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and efficacy of intravesical epinephrine instillation in patients with intractable lower urinary tract hematuria - A novel approach.

A. Chiu, Marcelo Chen, Y. Chow, 2023, Urology.

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Ying Cheng, C. Chiu, P. Janne, 2022, Cancer discovery.

Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.

Yih-Leong Chang, J. Shih, Chen‐Tu Wu, 2020, The oncologist.

The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia.

A. Ashraf, S. Fleming, A. Schwarer, 2019, Blood advances.

Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.

Jie Yang, J. Shih, Pan‐Chyr Yang, 2023, European journal of cancer.